<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03676101</url>
  </required_header>
  <id_info>
    <org_study_id>9-HPV-1001</org_study_id>
    <nct_id>NCT03676101</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females</brief_title>
  <official_title>A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Primary Immunogenicity of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Bovax Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chongqing Bovax Biopharmaceutical Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Bovax Biotechnology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and immunogenicity of the 9-valent Human Papillomavirus (Types 6, 11,
      16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female
      Subjects Aged 9-45 Years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Actual">January 10, 2020</completion_date>
  <primary_completion_date type="Actual">August 20, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Reporting Solicited Adverse Events</measure>
    <time_frame>7 days after each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events</measure>
    <time_frame>30 days after each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events</measure>
    <time_frame>30 days after third dose of vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) to HPV Types 6/11/16/18/31/33/45/52/58</measure>
    <time_frame>30 days after third dose of vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Cervical Cancers</condition>
  <condition>Vulvar Cancer</condition>
  <condition>Vaginal Cancer</condition>
  <condition>CIN1</condition>
  <condition>CIN2</condition>
  <condition>CIN 3</condition>
  <condition>AIS</condition>
  <condition>Invasive Carcinoma</condition>
  <condition>Mild Dysplasia of Vulva</condition>
  <condition>Moderate Dysplasia of Vulva</condition>
  <condition>Vin III</condition>
  <condition>VaIN1</condition>
  <condition>VaIN2</condition>
  <condition>VaIN3</condition>
  <condition>Genital Wart</condition>
  <arm_group>
    <arm_group_label>9-valent HPV Recombinant Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>9-valent HPV Recombinant Vaccine</intervention_name>
    <description>Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.</description>
    <arm_group_label>9-valent HPV Recombinant Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy females between, and including, 9 and 45 years of age at the time of enrolment

          -  Be able to provide legal identification for the sake of recruitment

          -  Be able to understand and sign informed consent form prior to enrollment and for
             subjects aged 9-17 years, they and their legal guardian(s) are supposed to understand
             and sign informed consent form together

          -  Subjects who the investigator believes that they can and will comply with the protocol
             requirements

          -  Subject must be not pregnant at the enrollment and agree to use adequate contraceptive
             precautions within 7 months or don't have pregnancy plan

        Exclusion Criteria:

          -  Fever or axillary temperature&gt; 37.0â„ƒ before vaccination

          -  Previous vaccination against HPV

          -  Planned administration/administration of investigational or non-registered product
             (drug or vaccine) other than the study vaccine within 30 days preceding first dose of
             vaccine

          -  Planned to take part in other clinical research within 7 months after participating
             this study or have taken part in other clinical research within 3 months before
             participating this study

          -  Abnormal laboratory tests parameters(except the part the clinician diagnosed as non
             clinical significance)

          -  Administration of any whole blood, plasma or immunoglobulins products within 3 months
             preceding first vaccination

          -  Interval between administration of the study vaccination and any attenuated live
             vaccine less than 14 days, and other vaccines less than 10 days

          -  History of serious allergic disease requiring medical intervention (such as oral and
             throat swelling, difficulty breathing, hypotension or shock)

          -  History of to adverse event to vaccine, or allergic to some food or drug

          -  History of epilepsy, seizures or convulsions, or family history of mental illness

          -  Subjects are immunocompromised or have been diagnosed as suffering from congenital or
             acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus
             erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis inflammation
             (JRA), inflammatory bowel disease or other autoimmune diseases, administration of
             immunosuppressants with six months prior to the first vaccine dose.

          -  Asplenia, functional asplenia, or any circumstances result of asplenia or splenectomy

          -  Subject to severe hepatorenal disease, cardiovascular disease, hypertension, diabetes,
             malignant tumor, all kinds of infectious diseases and acute illness, or during chronic
             disease acute attack period

          -  Medical diagnosis of coagulation abnormalities (eg, clotting factor deficiency,
             coagulation disorders, platelet anomaly) or obvious bruising or coagulation disorder

          -  Breastfeeding, pregnancy (including pregnancy test positive), or planned to be
             pregnant within 7 months

          -  During acute disease (including infectious and non-infectious disease) and chronic
             diease period of onset

          -  Abnormal cervical cancer screening or subject to CIN or acuteness wet wart that
             relevant to HPV infection in the past two years

          -  Planned to move out of local before the end of the study or leave the local for a long
             time during the study period

          -  Other unsuitable factors for the study judged by investigators
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhejiang Provincial Center for Disease Control and Prevention</name>
      <address>
        <city>Hanzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Condylomata Acuminata</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
    <mesh_term>Vaginal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

